Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study

BackgroundPrevious randomized controlled trials demonstrated a protective effect of renin angiotensin system blocking agents for the development of type-2 diabetes in patients with pre-diabetes. However, there are no real-world data available to illustrate the relevance for clinical practice.MethodsOpen, prospective, parallel group study comparing patients with an ACE inhibitor versus a diuretic based treatment. The principal aim was to document the first manifestation of type-2 diabetes in either group.ResultsA total of 2,011 patients were enrolled (mean age 69.1 ± 10.3 years; 51.6% female). 1,507 patients were available for the per-protocol analysis (1,029 ramipril, 478 diuretic group). New-onset diabetes was less frequent in the ramipril than in the diuretic group over 4 years. Differences were statistically different at a median duration of 3 years (24.4% vs 29.5%; p < 0.05). Both treatments were equally effective in reducing BP (14.7 ± 18.0/8.5 ± 8.2 mmHg and 12.7 ± 18.1/7.0 ± 8.3 mmHg) at the 4 year follow-up (p < 0.001 vs. baseline; p = n.s. between groups). In 38.6% and 39.7% of patients BP was below 130/80 mmHg (median time-to-target 3 months). There was a significant reduction of cardiovascular morbidity and mortality in favour of ramipril (p = 0.033). No significant differences were found for a change in HbA1c as well as for fasting blood glucose levels during follow-up. The rate of adverse events was higher in diuretic treated patients (SAE 15.4 vs. 12.4%; p < 0.05; AE 26.6 vs. 25.6%; p = n.s).ConclusionsRamipril treatment is preferable over diuretic based treatment regimens for the treatment of hypertension in pre-diabetic patients, because new-onset diabetes is delayed.

[1]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[2]  M. Pfeffer,et al.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.

[3]  Nicola J Cooper,et al.  Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis , 2007, BMJ : British Medical Journal.

[4]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[5]  W. Elliott,et al.  Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis , 2007, The Lancet.

[6]  L. Wilton,et al.  Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study , 1998, BMJ.

[7]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[8]  R. Ackermann,et al.  Reduced 10-Year Risk of Coronary Heart Disease in Patients Who Participated in a Community-Based Diabetes Prevention Program , 2009, Diabetes Care.

[9]  S. Yusuf,et al.  Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial , 2004, Diabetologia.

[10]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[11]  S. Yusuf,et al.  Ramipril and the development of diabetes. , 2001, JAMA.

[12]  S. Yusuf,et al.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial , 2008, The Lancet.

[13]  Jean-Claude Tardif,et al.  Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). , 2003, Circulation.

[14]  J. Rouleau,et al.  Effects of Angiotensin-Converting Enzyme Inhibition in Low-Risk Patients Early After Coronary Artery Bypass Surgery , 2008, Circulation.

[15]  C. Reid,et al.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.

[16]  A. Hofman,et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.

[17]  Dong-mei Jin,et al.  Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: a meta-analysis of 59,862 patients. , 2012, International journal of cardiology.

[18]  C. Reid,et al.  Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. , 2005, Journal of hypertension.

[19]  S. Matthaei,et al.  First-line antihypertensive treatment in patients with pre-diabetes: Rationale, design and baseline results of the ADaPT investigation , 2008, Cardiovascular diabetology.

[20]  A. Owen,et al.  Incident diabetes in clinical trials of antihypertensive drugs , 2007, The Lancet.

[21]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[22]  M. Sinno,et al.  Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis. , 2010, Cardiology journal.

[23]  G. Reboldi,et al.  Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects , 2004, Hypertension.

[24]  S. Yusuf,et al.  Effect of ramipril on the incidence of diabetes. , 2006, The New England journal of medicine.

[25]  E. Frohlich.  Treating hypertension - what are we to believe? , 2003, New England Journal of Medicine.

[26]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[27]  G. Remuzzi,et al.  Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus: The Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) Randomized Clinical Trial , 2011, Hypertension.

[28]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[29]  G. Mancia,et al.  Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial , 2006, Journal of hypertension.

[30]  T. Ogihara,et al.  Effects of Candesartan Compared With Amlodipine in Hypertensive Patients With High Cardiovascular Risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial , 2008, Hypertension.

[31]  L. Hansson.  Results of the STOP-Hypertension-2 trial. , 2000, Blood pressure. Supplement.

[32]  Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033–1046 , 2013, Diabetes Care.

[33]  D. E. Mathis,et al.  Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2005, Archives of internal medicine.

[34]  M. Nelson,et al.  Self‐reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2) , 2006, The Medical journal of Australia.

[35]  M. Caulfield,et al.  Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) , 2005, The Lancet.

[36]  C. Conti.  Cardiovascular diabetology. , 1999, Clinical cardiology.

[37]  E. Pfarr,et al.  Diagnosis of impaired glucose tolerance in hypertensive patients in daily clinical practice , 2005, International journal of clinical practice.

[38]  Keith C. Norris,et al.  Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  L. Lindholm,et al.  Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study) , 2003, Journal of hypertension.

[40]  J. O’Keefe,et al.  Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. , 2005, Journal of the American College of Cardiology.

[41]  G. Mancia,et al.  Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. , 2011, American journal of hypertension.

[42]  C. Berne,et al.  Insulin resistance is a characteristic feature of primary hypertension independent of obesity. , 1990, Metabolism: clinical and experimental.

[43]  H. Lehnert,et al.  Diabetogenic effect of antihypertensive treatment: primum nil nocere. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[44]  K. Fukao,et al.  O R I G I N a L I N V E S T I G a T I O N Open Access , 2022 .

[45]  S. Yusuf,et al.  Telmisartan to prevent recurrent stroke and cardiovascular events. , 2008, The New England journal of medicine.

[46]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.

[47]  M. Pfeffer,et al.  Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure , 2005, Circulation.

[48]  W. Elliott.  Prevention of Cardiovascular Events With an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required Versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Tri , 2006 .

[49]  S. Moebus,et al.  Impact of 4 different definitions used for the assessment of the prevalence of the Metabolic Syndrome in primary healthcare:The German Metabolic and Cardiovascular Risk Project (GEMCAS) , 2007, Cardiovascular diabetology.

[50]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[51]  Plamen Nikolov,et al.  Economic Costs of Diabetes in the U.S. in 2002 , 2003, Diabetes care.

[52]  M. Laakso,et al.  Effect of valsartan on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[53]  W. Elliott.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial , 2009 .

[54]  R. Califf,et al.  Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. , 2008, American heart journal.

[55]  J. Leahy.  Economic Costs of Diabetes in the U.S. in 2007 , 2008 .